Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Consensus PT from Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $16.88.

Several analysts recently weighed in on FOLD shares. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Bank of America increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. upped their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th.

Amicus Therapeutics Trading Down 0.5 %

Shares of Amicus Therapeutics stock opened at $9.79 on Friday. The firm has a 50-day moving average of $10.44 and a 200-day moving average of $10.60. Amicus Therapeutics has a 52-week low of $9.02 and a 52-week high of $14.57. The stock has a market cap of $2.93 billion, a PE ratio of -28.79 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total transaction of $98,762.50. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders have sold 30,401 shares of company stock valued at $339,363. 2.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its position in Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company’s stock valued at $255,936,000 after buying an additional 2,856,101 shares in the last quarter. William Blair Investment Management LLC increased its holdings in shares of Amicus Therapeutics by 12.8% during the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Amicus Therapeutics by 1.2% during the third quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock worth $70,499,000 after purchasing an additional 80,926 shares during the period. Fiera Capital Corp lifted its holdings in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock worth $52,382,000 after purchasing an additional 58,113 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Amicus Therapeutics by 4.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,160,027 shares of the biopharmaceutical company’s stock valued at $33,749,000 after purchasing an additional 139,491 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.